Nicholas Grund
Corporate Officer/Principal chez AKEBIA THERAPEUTICS, INC.
Fortune : 555 039 $ au 31/03/2024
Profil
Nicholas Grund is currently the Chief Commercial Officer at Akebia Therapeutics, Inc. He previously held positions as the Head-Specialty Care at Genzyme Corp from 2007 to 2015, the Chief Commercial Officer & Executive VP at AMAG Pharmaceuticals, Inc. from 2016 to 2019, and as the President-Eurofins at Transplant Genomics, Inc. from 2021 to 2022.
Mr. Grund also worked as a Principal at Bayer Diagnostics Corp.
from 1995 to 2002.
He holds an MBA from Northeastern University and an undergraduate degree from the University of Massachusetts.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/01/2024 | 303 300 ( 0,14% ) | 555 039 $ | 31/03/2024 |
Postes actifs de Nicholas Grund
| Sociétés | Poste | Début |
|---|---|---|
| AKEBIA THERAPEUTICS, INC. | Corporate Officer/Principal | 09/01/2024 |
Anciens postes connus de Nicholas Grund
| Sociétés | Poste | Fin |
|---|---|---|
Transplant Genomics, Inc.
 Transplant Genomics, Inc. BiotechnologyHealth Technology Transplant Genomics, Inc. operates as a molecular diagnostic company. It develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes and enable optimization of therapy. The company was founded by Daniel Salomon in 2013 and is headquartered in Mansfield, MA. | Corporate Officer/Principal | 01/11/2022 |
| AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29/03/2019 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/12/2015 |
| Bayer Diagnostics Corp. | Corporate Officer/Principal | 01/01/2002 |
Formation de Nicholas Grund
| Northeastern University | Masters Business Admin |
| University of Massachusetts | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Bayer Diagnostics Corp. | Health Technology |
Transplant Genomics, Inc.
Transplant Genomics, Inc. BiotechnologyHealth Technology Transplant Genomics, Inc. operates as a molecular diagnostic company. It develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes and enable optimization of therapy. The company was founded by Daniel Salomon in 2013 and is headquartered in Mansfield, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
